Anergis SA
BiopĂ´le  III
Route de la Corniche 9B
CH-1066 Epalinges
Tel: +41- 21 651 92 20
Fax: +41 21 651 92 21

Welcome to Anergis



Anergis is a clinical-stage biopharmaceutical company based in Switzerland.

Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast desensitization.

Anergis COP allergy vaccines are pharmaceutical-grade products based on Contiguous Overlapping Peptides (COPs) and only need to be administered for 2 months in order to achieve long-lasting desensitization.

If you are interested to participate in one of our clinical trials, please send an email to

Upload company presentation


27 February 2014
Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego

05 February 2014
Anergis Closes Financing Round Totaling CHF 8 M

14 January 2014
Anergis Obtains Core Technology Patent in Japan

18 December 2013
Anergis Appoints Dr. Dino Dina to its Board of Directors

21 October 2013
Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis' Birch Pollen Allergy Vaccine AllerT

27 September 2013
Anergis Receives Swiss Life Sciences Prize

see details